Cephalon Hit With FCA Suit Over Off-Label Marketing

Law360, New York (March 18, 2013, 8:14 PM EDT) -- Cephalon Inc. was hit with a whistleblower suit in New York federal court Friday claiming the drugmaker submitted hundreds of thousands of false claims to federal and state health care programs by promoting its leukemia and pain medications for unapproved off-label uses.

In the qui tam complaint, an unnamed plaintiff, a senior-level manager at Cephalon, accuses the company of violating federal and state False Claims Act laws, along with a host of other state statutes, by fraudulently marketing its leukemia drug Treanda and opioid analgesic Fentora...
To view the full article, register now.




Case Information

Case Title

United States of America ex rel. John Doe v. Cephalon, Inc., et al

Case Number



New York Southern

Nature of Suit

Other Statutory Actions


Sidney H. Stein

Date Filed

August 30, 2010

Law Firms


Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.